The OVATION 2 Study and the Novel Immunotherapy IMNN-001 for Ovarian Cancer – IMUNON
IMUNON posted on LinkedIn:
“ICYMI, our CEO Dr. Stacy Lindborg and gynecologic oncologist Dr. Premal Thaker recently shared their perspectives on the OVATION 2 study and its implications for ovarian cancer treatment in an interview with ONCOLife. They discussed the use of our innovative therapy alongside other treatments for newly diagnosed patients, highlighting the potential of our technology to strengthen anticancer immunity.
Their conversation also touched on promising study findings and the next steps in our clinical development pathway, as we explore applications across additional cancer types.
For more insights, watch the full interview.”
Hüseyin Kandemir, Editor in Chief at Health and Pharma, shared this post on LinkedIn, adding:
“It was a great pleasure to have this insightful interview with Dr. Stacy Lindborg and Dr. Premal Thaker, discussing their perspectives on the OVATION 2 study and its implications for ovarian cancer treatment, for ONCOLife.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023